Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide Anna Maria Raiola, Antonio Risitano, Nicoletta Sacchi, Livia Giannoni, Alessio Signori, Sara Aquino, Stefania Bregante, Carmen Di Grazia, Alida Dominietto, Simona Geroldi, Anna Ghiso, Francesca Gualandi, Teresa Lamparelli, Elisabetta Tedone, Maria Teresa Van Lint, Riccardo Varaldo, Adalberto Ibatici, Carlo Marani, Serena Marotta, Fabio Guolo, Daniele Avenoso, Lucia Garbarino, Fabrizio Pane, Andrea Bacigalupo, Emanuele Angelucci Biology of Blood and Marrow Transplantation Volume 24, Issue 1, Pages 119-126 (January 2018) DOI: 10.1016/j.bbmt.2017.10.002 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 (A) Kaplan-Meier probability of OS after myeloablative conditioning. Low mismatch versus high mismatch, P = .58. (B) Cumulative incidence of NRM after myeloablative conditioning. Low mismatch versus high mismatch, P = .93. Biology of Blood and Marrow Transplantation 2018 24, 119-126DOI: (10.1016/j.bbmt.2017.10.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 (A) Incidence of grades II to IV aGVHD after myeloablative conditioning. Low mismatch versus high mismatch, P = .13. (B) Cumulative incidence of moderate to severe cGVHD after myeloablative conditioning. Low mismatch versus high mismatch, P = .84. Biology of Blood and Marrow Transplantation 2018 24, 119-126DOI: (10.1016/j.bbmt.2017.10.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Cumulative incidence of relapse. Low mismatch versus high mismatch after myeloablative conditioning, P = .26. Biology of Blood and Marrow Transplantation 2018 24, 119-126DOI: (10.1016/j.bbmt.2017.10.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions